MannKind Corp Files 8-K Amendment
Ticker: MNKD · Form: 8-K/A · Filed: Dec 15, 2025 · CIK: 899460
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
Related Tickers: MNKD
TL;DR
MannKind filed an amendment to its 8-K on Oct 7, 2025, updating financial statements/exhibits.
AI Summary
MannKind Corporation filed an amendment (Amendment No. 1) to its Form 8-K on October 7, 2025. This amendment pertains to financial statements and exhibits, with the filing date being December 15, 2025. The company is incorporated in Delaware and its principal executive offices are located at 1 Casper Street, Danbury, Connecticut.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to financial statements or exhibits, which could impact the understanding of the company's financial position or disclosures.
Risk Assessment
Risk Level: low — This is a routine amendment to a previous filing, likely for administrative or disclosure clarification, and does not appear to indicate new material events.
Key Players & Entities
- MannKind Corporation (company) — Registrant
- October 07, 2025 (date) — Earliest event reported
- December 15, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- 1 Casper Street, Danbury, Connecticut 06810 (address) — Principal Executive Offices
FAQ
What is the purpose of this 8-K/A filing?
This filing is an amendment (Amendment No. 1) to a previously filed Form 8-K, specifically related to financial statements and exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is October 07, 2025.
When was this amendment filed with the SEC?
This amendment was filed as of date December 15, 2025.
Where are MannKind Corporation's principal executive offices located?
MannKind Corporation's principal executive offices are located at 1 Casper Street, Danbury, Connecticut 06810.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
Filing Stats: 1,089 words · 4 min read · ~4 pages · Grade level 10.6 · Accepted 2025-12-15 16:02:52
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share MNKD The Nasdaq Stock Mar
Filing Documents
- mnkd-20251007.htm (8-K/A) — 61KB
- mnkd-ex23_1.htm (EX-23.1) — 5KB
- mnkd-ex99_3.htm (EX-99.3) — 670KB
- 0001193125-25-319170.txt ( ) — 883KB
- mnkd-20251007.xsd (EX-101.SCH) — 25KB
- mnkd-20251007_htm.xml (XML) — 6KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (a) Financial Statements of Business Acquired The audited consolidated financial statements of scPharma as of and for the year ended December 31, 2024 and the related notes thereto have been audited by RSM US LLP, scPharma's independent auditor, as set forth in its report thereon, are incorporated herein by reference as Exhibit 99.1. The unaudited interim condensed consolidated financial statements of scPharma as of and for the three and six months ended June 30, 2025 and the related notes thereto are incorporated herein by reference as Exhibit 99.2. (b) Pro Forma Financial Information The unaudited pro forma condensed combined financial information of the Company as of and for the six months ended June 30, 2025 and the year ended December 31, 2024 is attached hereto as Exhibit 99.3 and incorporated herein by reference. (d) Exhibits. 2.1# Agreement and Plan of Merger, dated August 24, 2025, by and among MannKind Corporation, Seacoast Merger Sub, Inc. and scPharmaceuticals Inc. (incorporated by reference to Exhibit 2.1 to MannKind Corporation's Current Report on Form 8-K (File No. 000-50865), filed with the SEC on August 25, 2025). 10.1 Contingent Value Rights Agreement, dated as of October 7, 2025, by and between MannKind Corporation and Broadridge Corporate Issuer Solutions, LLC (previously filed with the Original Report). 10.2 Amendment No.1 to the Loan Agreement, dated August 24, 2025, among MannKind Corporation, certain subsidiaries of MannKind Corporation, Wilmington Trust, National Association, Blackstone Alternative Credit Advisors LP and the lenders from time to time party thereto (incorporated by reference to Exhibit 10.2 to MannKind Corporation's Current Report on Form 8-K (file No. 000-50865), filed with the SEC on August 25, 2025). 23.1 Consent of RSM US LLP. 99.1 Audited Consolidated Financial Statements of scPharmaceuticals Inc. and its consolidated subsidiary as of and for th